Bioventus Inc. (BVS)
BVS trades on Nasdaq in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1665988/000166598826000011/0001665988-26-000011-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BVS on Nasdaq |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001665988 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $568.1M |
| Net income | $22.7M |
| Operating income | $54.0M |
| Net margin | 4.0% |
| Operating margin | 9.5% |
| Revenue growth | -0.9% |
| Cash | $51.2M |
| Total assets | $683.6M |
| P/E (computed) | 38.8× |
| P/S (computed) | 1.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $30.7M cash; operating cash flow $21.9M a quarter. | Report 2026-09-26 |
| Shares outstanding | 84,260,956 (2026-10-23); 82,763,214 a year earlier. | Cover page 2026-10-23 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $313K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-26 | $142.4M | $6.0M | $20.7M | $30.7M | $229.8M | $585.6M | 10-Q 2026-11-02 |
| Q2 2026 2026-06-27 | $153.2M | $33.4M | $19.9M | $29.5M | $248.5M | $581.8M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-28 | $132.1M | $3.1M | $8.9M | $35.8M | $272.1M | $576.3M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $157.9M | $14.8M | $38.0M | $51.2M | $294.0M | $568.1M | 10-K 2026-03-05 |
| Q3 2025 2025-09-27 | $138.7M | $3.2M | $30.1M | $42.2M | $322.6M | $563.8M | 10-Q 2026-11-02 |
| Q2 2025 2025-06-28 | $147.7M | $7.5M | $25.9M | $32.9M | $341.2M | $564.1M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-29 | $123.9M | -$2.6M | -$19.3M | $22.8M | $345.9M | $567.7M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $153.6M | -$388K | $19.3M | $41.6M | $335.6M | $573.3M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2024-11-04 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-11-02 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 464 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.5% |
| 1 month | -21.4% |
| 3 months | -23.3% |
| Year to date | +43.3% |
| 1 year | +40.8% |
| From 52-week high | -30.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| AORT | Artivion Inc. | $18.47 | -3.30% | $901.1M |
| BBNX | Beta Bionics Inc. | $15.21 | -7.37% | $826.9M |
| KIDS | OrthoPediatrics Corp. | $31.50 | -2.63% | $822.5M |
| ATEC | Alphatec Holdings Inc. | $6.78 | -4.10% | $1.1B |
| SIBN | SI-BONE Inc. | $23.41 | -0.13% | $1.1B |
| SGP | SpyGlass Pharma Inc. | $32.24 | -1.95% | $1.1B |
| IRMD | iRadimed Corporation | $84.84 | -0.60% | $1.1B |
| IART | Integra LifeSciences Holdings Corporation | $13.98 | -2.92% | $1.1B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier